Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00986362 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial of Intravitreal Microplasmin in Infants and Children Scheduled for Vitrectomy
A Phase 2 study, sponsored by ThromboGenics.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT00986362 is a Phase 2 study that has completed, run by ThromboGenics. The registered enrollment target is 24 participants.
The verdict
NCT00986362, a Phase 2 study, has completed, sponsored by ThromboGenics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
To evaluate the safety and preliminary efficacy of intravitreal microplasmin as an adjunct to conventional vitrectomy for the treatment of pediatric patients.
Interventions
- DRUG Placebo
- DRUG Ocriplasmin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2010-02 |
| Est. Completion | 2012-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00986362
The ClinicalTrials.gov registry entry for NCT00986362 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ThromboGenics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00986362 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00986362 about?
NCT00986362 is a clinical study titled "Clinical Trial of Intravitreal Microplasmin in Infants and Children Scheduled for Vitrectomy". To evaluate the safety and preliminary efficacy of intravitreal microplasmin as an adjunct to conventional vitrectomy for the treatment of pediatric patients.
What is the current status of trial NCT00986362?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2010-02. Estimated completion is 2012-04.
What interventions are being tested in trial NCT00986362?
The interventions under investigation include: Placebo (DRUG), Ocriplasmin (DRUG).
Who is sponsoring clinical trial NCT00986362?
This trial is sponsored by ThromboGenics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.